We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

SD BIOSENSOR

SD BIOSENSOR develops immunological and molecular diagnostics and blood glucose self-monitoring systems, glycated hem... read more Featured Products: More products

Download Mobile App




Point-of-Care Diagnostic to Identify G6PD Deficiency Evaluated

By LabMedica International staff writers
Posted on 31 Aug 2021
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an inherited condition in which patients are excessively susceptible to the development of hemolytic anemia. More...
Affected people lack the ability to tolerate biochemical oxidative stress, and red cell hemolysis is the most important clinical consequence.

People with G6PD deficiency are at risk of hemolysis when exposed to certain medications, including 8-aminoquinoline drugs used to treat Plasmodium vivax malaria. The diagnosis of G6PD deficiency is made by a quantitative spectrophotometric analysis or, more commonly, by a rapid fluorescent spot test detecting the generation of NADPH from NADP. The test is positive if the blood spot fails to fluoresce under ultraviolet light.

Scientists specializing in Tropical Medicine from the Amazonas State University (Manaus, Brazil) and their international colleagues collected venous samples were from 1,662 participants, and capillary samples were available from 1,693 participants. Microscopic examinations of thick blood slides were conducted to determine malaria diagnosis. The performance of the semi-quantitative point-of-care G6PD test, STANDARD G6PD Test (SD Biosensor, Suwon, Republic of Korea). Both capillary and venous specimens were compared to matching G6PD values from venous specimens tested with a spectrophotometric reference assay normalized by hemoglobin.

The quantitative G6PD reference assay was run in duplicate using the Pointe Scientific reagent kit (Pointe Scientific, Canton, MI, USA) on a Shimadzu UV-1800 six-cell temperature-regulated manual spectrophotometer (Kyoto, Japan). Each specimen was also tested using the Trinity qualitative G6PD FST kit (G-6-PDH Screen by Spot Test, Trinity Biotech, Bray, Ireland). Hemoglobin concentration was determined within 24 hours using a KX-21N automated hematology analyzer (Sysmex, Kobe, Japan) and the HemoCue 201+ test (HemoCue AB, Ångelholm, Sweden) and run on aliquoted venous blood in the laboratory within 24 hours of sample collection.

The scientists reported that in comparison to spectrophotometry, the STANDARD G6PD Test performed equivalently in determining G6PD status in venous and capillary specimens under varied operating temperatures. Using the manufacturer-recommended reference value thresholds, the test’s sensitivity at the <30% threshold on both specimen types was 100%. Specificity was 98.6% on venous specimens and 97.8% on capillary. At the 70% threshold, the test’s sensitivity was 96.9% on venous specimens and 94.3% on capillary. Specificity was 96.5% and 92.3% on venous and capillary specimens, respectively.

The authors concluded that their data showed that the STANDARD G6PD Test performed well in comparison to the spectrophotometric reference standard. The STANDARD G6PD Test is a promising tool to aid in the identification of G6PD deficiency in Brazil. The availability of this test represents an important opportunity to improve management of P. vivax malaria cases in resource-limited settings, where reliable alternatives to quantitative spectrophotometry are needed to expand access to radical cure. The study was published on August 12, 2021 in the journal PLOS Neglected Tropical Diseases.

Related Links:
Amazonas State University
SD Biosensor
Pointe Scientific
Shimadzu
Trinity Biotech
HemoCue AB



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.